IPV

Sinovac announced last week that China’s National Medical Products Administration has approved its Sabin-based inactivated polio vaccine (sIPV).

In its press release, the Chinese biotech said that WHO accepted its prequalification materials in early 2020 and completed site inspections this February. If prequalified, Sinovac’s sIPV would become the second Sabin-based product to gain the status after LG Chem’s in January 2021.

The Beijing Institute of Biological Products and…

WHO released detailed notes last week from the March 22-24 virtual meeting of its Strategic Advisory Group of Experts (SAGE) on Immunization.

As in the last SAGE meeting in October 2020, the impact of the pandemic on immunization as well as guidance on Covid-19 vaccines dominated the discussion. WHO’s Immunization, Vaccines and Biologicals (IVB) department director compared the scope of Covid-19 to that of the 1918 influenza pandemic. IVB noted, however, “promising signs” of response…

The Lancet Infectious Diseases published a meta-analysis last week of studies comparing the immunogenicity of one-, two- or three-dose regimens of fractional inactivated polio vaccine (fIPV) versus full-dose IPV when used against the three polio serotypes in children age 5 and under.

The researchers reported that seroconversion following a three-dose schedule of fIPV showed “no substantial difference” from three doses of full-dose IPV, but that the full dose gives higher titers of…

An update last week to UNICEF Supply Division’s price list for inactivated polio vaccine (IPV) shows that South Korea-based LG Chem’s recently prequalified Sabin-based shot is now the lowest-cost five-dose IPV available.

LG Chem’s price is $1.75 per dose in 2021 and falls to $1.50 in 2022. Denmark’s AJ Vaccines has the next cheapest five-dose IPV at $2.45 per dose in 2021 and as low as $1.90 in 2022. Serum Institute of India’s Bilthoven-manufactured shot is 80% more costly than its…

WHO added LG Chem’s Sabin-based inactivated polio vaccine (sIPV) to its list of prequalified products last month, making the shot the first PQ’d IPV to use the safer attenuated Sabin poliovirus.

In 2014, GSK accidentally spilled 45 liters of liquid contaminated by the wild-type Salk poliovirus into a Belgian river.

The third edition of WHO’s Global Action Plan to minimize poliovirus facility-associated risk (GAP III, published in 2015) opposed new Salk IPV facilities because of…

Mentions:

The Lancet published Phase 3 results last week from a Gates Foundation-funded study showing that three doses of fractional inactivated polio vaccine (fIPV) administered intradermally at 10, 14 and 36 weeks resulted in broad immunity against poliovirus type 1 and 2 and was non-inferior to the same regimen of intramuscular IPV. A two-dose schedule of fIPV was also non-inferior to two full doses of IPV, and seroconversion rates for fIPV were higher when doses were given at 14 and 36 weeks than…

Mentions:

Batavia Biosciences and Valneva announced this week that they would work together to “accelerate market access” to a low-cost inactivated polio vaccine (IPV), according to a joint press release.

For an undisclosed upfront payment and monthly service fees, Valneva’s Swedish subsidiary will manufacture Sabin-based IPV using Batavia's low-cost HIP-VAX manufacturing process in combination with Univercells' NevoLine micro-facility technology. France’s Batavia will supply the…

AJ Vaccines announced today that WHO has prequalified Picovax, its low-dose, adjuvanted inactivated polio vaccine.

According to the press release, the Denmark-based company expects first deliveries of the vaccine to UNICEF and PAHO by mid-2020, with capacity for up to 100 million doses over the next five years.

AJ Vaccines took over Picovax in January 2017 after acquiring Statens Serum Institut’s manufacturing facilities from the Danish government. The Gates Foundation supported…

This month’s issue of Vaccine published findings showing that the first large-scale use of Colorado-based PharmaJet’s needle-free jet injector technology improved polio coverage rates by 18.4 percent. The study evaluated historical campaigns for administering inactivated poliovirus vaccine with one last year that used the new technology to give fractional doses to children in Karachi, Pakistan.

According to a PharmaJet press release, 97.6 percent of vaccinators and 99.6 percent of…

Mentions:

PLOS ONE published findings last week showing that a novel gamma radiation-inactivated, Sabin-based polio vaccine generated “equivalent or improved” neutralizing antibody responses in rats compared with marketed IPV products.

The researchers from Maryland-based Biological Mimetics and Uniformed Services University said their inactivation approach was “simpler, faster and less costly” than using today’s formaldehyde method and could be adapted to any pathogen of interest—including…